Vigil Neuroscience (VIGL)
(Delayed Data from NSDQ)
$8.05 USD
0.00 (0.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $8.06 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VIGL 8.05 0.00(0.00%)
Will VIGL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIGL
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?
VIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
Other News for VIGL
Catalyst Watch: Palantir earnings, Firefly Aerospace IPO, OPEC+, and the Fed's SLOOS report
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
Tesla, Alphabet Set To Report Earnings As Investors Watch Out For Jobless Claims And Durable Goods Orders
Catalyst Watch: Alphabet earnings, McGraw Hill IPO, Trump talks AI, and more robotaxi buzz
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact